--- title: "AI Act and Pharmaceuticals: Compliance for German Pharma (2026)" description: "How the EU AI Act affects drug discovery, clinical trials, and pharmaceutical AI in Germany." image: "https://compound.law/assets/images/og-image-en.webp" source: "https://compound.law/en-DE/ai-act/pharmaceuticals/" language: "en" --- ![AI in Pharmaceuticals](https://compound.law/assets/images/ai-act/ai_act_2.webp) ai-act # AI Act and Pharmaceuticals: Compliance for German Pharma (2026) 29 January 2026 Pharmaceutical AI is accelerating drug discovery, optimizing clinical trials, and transforming manufacturing. Much of this happens in research environments with regulatory flexibility. But when AI moves toward patients or production, compliance requirements engage. Our [EU AI Act compliance overview](https://compound.law/en-DE/ai-act/) explains the risk-tier framework that determines when those requirements kick in. German pharma companies need to understand where research freedom ends and regulation begins. ## Drug Discovery Has Flexibility AI for target identification, compound screening, molecular design—research tools without direct patient impact. The AI Act doesn’t heavily regulate research AI. Develop what you need, document what you do, but don’t expect compliance burdens on early-stage discovery. Our [AI drug discovery compliance guide](https://compound.law/en-DE/compliance/ai-drug-discovery/) explains exactly where that boundary sits and how to document your research AI appropriately. The freedom exists because patients aren’t yet affected. When AI moves toward clinical application, rules change. ## Clinical Trials and Patient AI AI used in clinical trials that affects patient selection, dosing, or treatment decisions triggers higher obligations. Patient safety is paramount. If AI influences clinical decisions, medical device and AI Act requirements likely apply. See our [AI medical diagnosis compliance](https://compound.law/en-DE/compliance/ai-medical-diagnosis/) resource for how these requirements translate into clinical AI obligations. AI for trial optimization—site selection, recruitment, protocol design—is generally lower risk administrative tooling. ## Manufacturing and Quality Pharmaceutical manufacturing AI for quality control, process optimization, and production monitoring operates under GMP requirements. The AI Act adds to these obligations for AI-specific risks, but existing pharmaceutical quality frameworks provide a strong foundation. If AI is a safety component in manufacturing, classification increases. ## AI in Regulated Processes: GxP and EU AI Act Compound Law advises pharmaceutical companies in Germany and the DACH region on EU AI Act compliance for regulated processes — from risk classification to GAMP 5-compatible documentation. **Regulated processes** in pharma cover all GxP environments: GMP (Good Manufacturing Practice), GCP (Good Clinical Practice), and GVP (Good Pharmacovigilance Practice). AI systems deployed in these environments must comply simultaneously with the EU AI Act and existing GxP requirements — with significant overlap in documentation, validation, and change control obligations. ### GxP Areas and AI Act Classification - **GMP (Good Manufacturing Practice):** AI for quality control, process optimization, and production monitoring qualifies as high-risk AI (Annex III) when it performs a safety function. Our [AI quality control compliance guide](https://compound.law/en-DE/compliance/ai-quality-control/) explains the specific obligations. - **GCP (Good Clinical Practice):** AI in clinical trials affecting patient selection, dosing, or patient matching triggers elevated compliance obligations — particularly in combination with medical device requirements. - **GVP (Good Pharmacovigilance Practice):** AI for signal detection in pharmacovigilance carries compliance obligations that depend on its influence over safety decisions. - **Quality Management Systems (QMS):** AI-assisted document review and change control must be integrated into GAMP 5 validation frameworks. ### What Regulated Pharma Companies Must Do Now 1. **Risk classification** of each AI system in GxP scope under EU AI Act Annex III 2. **Validation alignment** with existing GAMP 5 and ICH E9 requirements 3. **Documentation obligations** under AI Act Art. 11–17 structured in parallel with GMP documentation 4. **Notified body involvement** for high-risk AI in a medical device context (Art. 28 EU AI Act) 5. **Interface analysis** between AI Act requirements and the existing quality management system Pharma companies that integrate AI Act and GxP compliance early avoid duplicating documentation efforts and are better prepared for regulatory inspections. ## What This Means Practically Pharma companies should map AI by phase and function. Research AI has flexibility. Patient-affecting AI needs medical device and AI Act compliance. Manufacturing AI integrates with GMP. The transition from research to clinical application is the critical compliance trigger. Document-intensive workflows across the pipeline benefit from our [AI document analysis compliance](https://compound.law/en-DE/compliance/ai-document-analysis/) guide. For infrastructure, [AWS Bedrock](https://compound.law/en-DE/tools/aws-bedrock/) and [Azure OpenAI](https://compound.law/en-DE/tools/azure-openai/) are the leading enterprise platforms with GxP-relevant compliance documentation. ## How Compound Law Helps - AI classification across development phases - Clinical trial AI compliance - Manufacturing AI integration - Regulated processes and GxP compliance - Regulatory submission support - Research to commercialization transition ## Frequently Asked Questions **Is drug discovery AI regulated?** Research AI has flexibility. Heavy regulation begins when AI affects patients or enters clinical application. **What about AI in clinical trials?** Patient-affecting AI needs full compliance. Trial optimization tools are generally lower risk. **Does GMP cover AI requirements?** Partly. GMP provides foundation, but AI Act adds AI-specific requirements for manufacturing AI. **Does the EU AI Act apply to GxP-regulated AI systems in Germany?** Yes. AI systems deployed in GxP-regulated environments — GMP, GCP, and GVP — are subject to EU AI Act requirements in Germany and across the EU. The risk classification under Annex III of the EU AI Act applies to AI performing safety-relevant functions in manufacturing, clinical trials, and pharmacovigilance. The obligations overlap substantially with existing GxP requirements, particularly around documentation, validation, and change control. Pharmaceutical companies must assess each AI system individually and implement the technical documentation requirements under Articles 11–17. Compound Law advises pharma companies in Germany and the DACH region on aligning EU AI Act obligations with GAMP 5 and ICH requirements. **What is the EU AI Act deadline for pharmaceutical companies in 2026?** The EU AI Act’s high-risk AI provisions become mandatory on 2 August 2026. For pharmaceutical companies, this means AI systems in GxP-regulated processes — particularly those performing safety-relevant functions in manufacturing, clinical trials, or pharmacovigilance — must meet full documentation, conformity assessment, and quality management obligations by that date. Companies that have not yet classified their AI systems or begun compliance work should act immediately; the compliance window is now short. The deadline also applies to AI diagnostic tools qualifying as medical devices, where MDR conformity assessment is recognised under Article 28 EU AI Act but does not replace the substantive AI Act requirements. **Who can help pharmaceutical companies implement the EU AI Act for regulated processes?** Compound Law advises pharmaceutical companies in Germany and the DACH region on EU AI Act compliance for regulated processes — from risk classification to GAMP 5-compatible documentation and notified body coordination. Our team covers the full compliance scope: GxP interface analysis, technical documentation under Articles 11–17, quality management system integration, and post-market monitoring obligations. We work with pharmaceutical companies of all sizes, from large DACH manufacturers to clinical-stage biotechs entering regulated processes. See our [AI medical diagnosis compliance guide](https://compound.law/en-DE/compliance/ai-medical-diagnosis/) and [healthcare AI Act page](https://compound.law/en-DE/ai-act/healthcare/) for related MDR and MedTech compliance considerations. ## Related Industry Guides [![EU AI Act timeline Germany for 2 August 2026 2 December 2027 and 2 August 2028](https://compound.law/assets/images/ai-act/ai_act_1.webp)](https://compound.law/en-DE/ai-act/august-2026-deadline/) [ai-act](https://compound.law/en-DE/ai-act/august-2026-deadline/) ### [EU AI Act Timeline Germany: 2 August 2026, 2027 and 2028](https://compound.law/en-DE/ai-act/august-2026-deadline/) [EU AI Act 2 August 2026 is not the only date. German businesses need the split timeline for transparency, stand-alone high-risk AI, and product AI.](https://compound.law/en-DE/ai-act/august-2026-deadline/) [![EU AI Act compliance requirements for financial services firms in Germany](https://compound.law/assets/images/ai-act/ai_act_4.webp)](https://compound.law/en-DE/ai-act/financial-services/) [ai-act](https://compound.law/en-DE/ai-act/financial-services/) ### [EU AI Act Financial Services Compliance Guide for Germany (updated 2026)](https://compound.law/en-DE/ai-act/financial-services/) [Which AI systems are high-risk in financial services, what August 2026 deadlines mean for German banks, and a practical compliance checklist.](https://compound.law/en-DE/ai-act/financial-services/) [![EU AI Act high-risk insurance compliance Germany underwriting claims](https://compound.law/assets/images/ai-act/ai_act_4.webp)](https://compound.law/en-DE/ai-act/insurance/) [ai-act](https://compound.law/en-DE/ai-act/insurance/) ### [EU AI Act for German Insurers: High-Risk AI Compliance Guide](https://compound.law/en-DE/ai-act/insurance/) [EU AI Act classifies insurance AI as high-risk. Underwriting, pricing, and claims obligations for German insurers — with a practical compliance checklist.](https://compound.law/en-DE/ai-act/insurance/) ## Frequently asked questions Research AI has flexibility. Heavy regulation begins when AI affects patients or enters clinical application. Patient-affecting AI needs full compliance. Trial optimization tools are generally lower risk. Partly. GMP provides foundation, but AI Act adds AI-specific requirements for manufacturing AI. Yes. AI systems deployed in GxP-regulated environments — GMP, GCP, and GVP — are subject to EU AI Act requirements in Germany and across the EU. The risk classification under Annex III of the EU AI Act applies to AI performing safety-relevant functions in manufacturing, clinical trials, and pharmacovigilance. The obligations overlap substantially with existing GxP requirements, particularly around documentation, validation, and change control. Pharmaceutical companies must assess each AI system individually and implement the technical documentation requirements under Articles 11–17. Compound Law advises pharma companies in Germany and the DACH region on aligning EU AI Act obligations with GAMP 5 and ICH requirements. The EU AI Act's high-risk AI provisions become mandatory on 2 August 2026. For pharmaceutical companies, this means AI systems in GxP-regulated processes — particularly those performing safety-relevant functions in manufacturing, clinical trials, or pharmacovigilance — must meet full documentation, conformity assessment, and quality management obligations by that date. Companies that have not yet classified their AI systems or begun compliance work should act immediately; the compliance window is now short. The deadline also applies to AI diagnostic tools qualifying as medical devices, where MDR conformity assessment is recognised under Article 28 EU AI Act but does not replace the substantive AI Act requirements. Compound Law advises pharmaceutical companies in Germany and the DACH region on EU AI Act compliance for regulated processes — from risk classification to GAMP 5-compatible documentation and notified body coordination. Our team covers the full compliance scope: GxP interface analysis, technical documentation under Articles 11–17, quality management system integration, and post-market monitoring obligations. We work with pharmaceutical companies of all sizes, from large DACH manufacturers to clinical-stage biotechs entering regulated processes. See our \[AI medical diagnosis compliance guide]\(/en-DE/compliance/ai-medical-diagnosis/) and \[healthcare AI Act page]\(/en-DE/ai-act/healthcare/) for related MDR and MedTech compliance considerations. ## Structured data ```json [ { "@context": "https://schema.org", "@type": [ "Organization", "LegalService" ], "@id": "https://compound.law/#organization", "name": "Compound Law", "alternateName": "Compound Law — AI Law Firm", "url": "https://compound.law/", "logo": { "@type": "ImageObject", "url": "https://compound.law/press/logos/PNG/Compound_Law_Icon.png", "width": 1024, "height": 1024 }, "image": "https://compound.law/assets/images/og-image.webp", "description": "The AI-native law firm in Berlin for start-ups, mid-sized companies and corporates: commercial and contract law, data protection, the EU AI Act, trademarks, corporate law, and restructuring and insolvency. A lawyer reviews every result, billed at a flat fee.", "foundingDate": "2026", "founder": [ { "@type": "Person", "name": "Marko Bradic", "jobTitle": "CEO", "url": "https://compound.law/en-DE/tech-team/marko-bradic/", "sameAs": [ "https://www.linkedin.com/in/markobradic/" ], "knowsAbout": [ "Product strategy and development", "Scaling technology companies", "FinTech and financial services", "AI-powered product innovation", "Business operations and growth", "Digital transformation" ] }, { "@type": "Person", "name": "Mohit Tilwani", "jobTitle": "CTO", "url": "https://compound.law/en-DE/tech-team/mohit-tilwani/", "sameAs": [ "https://www.linkedin.com/in/mohit-tilwani/" ], "knowsAbout": [ "Engineering leadership and architecture", "Scaling high-traffic systems", "AI and machine learning infrastructure", "FinTech platform development", "Cloud infrastructure and DevOps", "Product engineering" ] }, { "@type": "Person", "name": "Julian Jantze", "jobTitle": "Rechtsanwalt", "url": "https://compound.law/en-DE/lawyers/julian-jantze/", "sameAs": [ "https://www.linkedin.com/in/julian-jantze-957b95158/" ], "knowsAbout": [ "Corporate law and corporate governance for technology companies", "Employment law and HR compliance", "EU AI Act compliance and AI governance", "Employee participation models (VSOP/ESOP)", "Regulatory compliance for tech companies", "Legal operations and Legal Tech implementation" ] } ], "employee": [ { "@type": "Person", "name": "Marko Bradic", "jobTitle": "CEO", "url": "https://compound.law/en-DE/tech-team/marko-bradic/", "sameAs": [ "https://www.linkedin.com/in/markobradic/" ], "knowsAbout": [ "Product strategy and development", "Scaling technology companies", "FinTech and financial services", "AI-powered product innovation", "Business operations and growth", "Digital transformation" ] }, { "@type": "Person", "name": "Mohit Tilwani", "jobTitle": "CTO", "url": "https://compound.law/en-DE/tech-team/mohit-tilwani/", "sameAs": [ "https://www.linkedin.com/in/mohit-tilwani/" ], "knowsAbout": [ "Engineering leadership and architecture", "Scaling high-traffic systems", "AI and machine learning infrastructure", "FinTech platform development", "Cloud infrastructure and DevOps", "Product engineering" ] }, { "@type": "Person", "name": "Julian Jantze", "jobTitle": "Rechtsanwalt", "url": "https://compound.law/en-DE/lawyers/julian-jantze/", "sameAs": [ "https://www.linkedin.com/in/julian-jantze-957b95158/" ], "knowsAbout": [ "Corporate law and corporate governance for technology companies", "Employment law and HR compliance", "EU AI Act compliance and AI governance", "Employee participation models (VSOP/ESOP)", "Regulatory compliance for tech companies", "Legal operations and Legal Tech implementation" ] }, { "@type": "Person", "name": "Marc Schuba", "jobTitle": "Founding Partner, Rechtsanwalt (German attorney)", "url": "https://compound.law/en-DE/lawyers/marc-schuba/", "sameAs": [ "https://www.linkedin.com/in/marcschuba/" ], "knowsAbout": [ "IP and IT law", "SaaS and IT contracts, IT outsourcing", "Software and open-source licensing", "Data protection law (GDPR)", "AI law and the EU AI Act" ] }, { "@type": "Person", "name": "Dr. Markus Dreißigacker", "jobTitle": "Rechtsanwalt", "url": "https://compound.law/en-DE/lawyers/markus-dreissigacker/", "sameAs": [ "https://www.linkedin.com/in/markusdreissigacker" ], "knowsAbout": [ "M&A (Due diligence, post-merger integration, IPO readiness)", "Corporate Law (Governance, board work, restructuring)", "Commercial Law (Customer contracts, supplier agreements, NDAs)", "IP (Trademark management, IP transfer agreements)", "Compliance & ESG (Global compliance programs, human rights, sustainability)", "Data Protection (GDPR strategy, DPO experience, privacy programs)" ] }, { "@type": "Person", "name": "Philipp Brandt", "jobTitle": "Partner, Rechtsanwalt (German attorney), Specialist Lawyer for Intellectual Property Law", "url": "https://compound.law/en-DE/lawyers/philipp-brandt/", "sameAs": [ "https://www.linkedin.com/in/philipp-brandt-81b446a/" ], "knowsAbout": [ "Restructuring and insolvency law (crisis advice for management, protective shield and insolvency plan proceedings, insolvency administration)", "Intellectual property (trademarks, unfair competition, copyright, trade secrets, licence agreements)", "Data protection law (data breaches, regulatory fine proceedings, access and damages claims)", "Distribution and commercial law (distribution agreements, acquisition and sale of industrial plants)" ] } ], "address": { "@type": "PostalAddress", "addressLocality": "Berlin", "addressCountry": "DE" }, "areaServed": [ "Germany", "Austria", "Switzerland", "European Union", "United Kingdom", "United States", "Singapore" ], "availableLanguage": [ "de", "en" ], "serviceType": [ "AI law firm", "AI-native legal services", "legal counsel for start-ups and growth companies", "legal counsel for mid-sized companies and corporates", "Commercial Law", "Corporate Law", "Employment Law", "Regulatory & Compliance", "Intellectual Property", "Insolvency & Restructuring" ], "hasOfferCatalog": { "@type": "OfferCatalog", "name": "Compound Law services", "itemListElement": [ { "@type": "Offer", "itemOffered": { "@type": "Service", "name": "Commercial Contracts", "description": "Battle-tested contracts for your sales process", "serviceType": [ "enterprise contracts", "MSA", "DPA", "sales contracts" ], "areaServed": [ "Germany", "European Union", "United Kingdom", "United States", "Singapore" ] } }, { "@type": "Offer", "itemOffered": { "@type": "Service", "name": "International Employment", "description": "Compliant hiring across borders", "serviceType": [ "international employment", "hiring abroad", "employment contracts" ], "areaServed": [ "Germany", "European Union", "United Kingdom", "United States", "Singapore" ] } }, { "@type": "Offer", "itemOffered": { "@type": "Service", "name": "VSOP/ESOP Setup", "description": "Employee participation that actually works", "serviceType": [ "VSOP", "ESOP", "employee stock options", "equity incentives" ], "areaServed": [ "Germany", "European Union", "United Kingdom", "United States", "Singapore" ] } }, { "@type": "Offer", "itemOffered": { "@type": "Service", "name": "Funding Round Support", "description": "Clean legal for your next raise", "serviceType": [ "funding round", "term sheet", "SHA", "due diligence", "cap table" ], "areaServed": [ "Germany", "European Union", "United Kingdom", "United States", "Singapore" ] } }, { "@type": "Offer", "itemOffered": { "@type": "Service", "name": "Corporate Housekeeping", "description": "Get your legal house in order", "serviceType": [ "corporate governance", "board resolutions", "shareholder register" ], "areaServed": [ "Germany", "European Union", "United Kingdom", "United States", "Singapore" ] } }, { "@type": "Offer", "itemOffered": { "@type": "Service", "name": "Data Protection & Privacy", "description": "GDPR compliance that doesn't slow you down", "serviceType": [ "GDPR", "data protection", "privacy", "DPA", "cookies", "data breach response", "GDPR fines", "Art. 82 GDPR" ], "areaServed": [ "Germany", "European Union", "United Kingdom", "United States", "Singapore" ] } }, { "@type": "Offer", "itemOffered": { "@type": "Service", "name": "AI Act Compliance", "description": "Navigate EU AI regulation", "serviceType": [ "AI Act", "AI compliance", "AI governance", "EU AI regulation" ], "areaServed": [ "Germany", "European Union", "United Kingdom", "United States", "Singapore" ] } }, { "@type": "Offer", "itemOffered": { "@type": "Service", "name": "IP & Competition", "description": "Protect and enforce what you've built", "serviceType": [ "IP protection", "intellectual property", "trademarks", "trademark enforcement", "warning letters", "preliminary injunctions", "unfair competition", "software licensing", "open source compliance" ], "areaServed": [ "Germany", "European Union", "United Kingdom", "United States", "Singapore" ] } }, { "@type": "Offer", "itemOffered": { "@type": "Service", "name": "Fractional General Counsel", "description": "In-house legal without the full-time cost", "serviceType": [ "fractional GC", "fractional general counsel", "outsourced legal", "legal retainer" ], "areaServed": [ "Germany", "European Union", "United Kingdom", "United States", "Singapore" ] } }, { "@type": "Offer", "itemOffered": { "@type": "Service", "name": "FinTech Compliance", "description": "Navigate financial regulation", "serviceType": [ "fintech compliance", "BaFin", "banking regulation", "AML", "KYC" ], "areaServed": [ "Germany", "European Union", "United Kingdom", "United States", "Singapore" ] } }, { "@type": "Offer", "itemOffered": { "@type": "Service", "name": "Legal Retainer", "description": "Predictable legal support when you need it", "serviceType": [ "legal retainer", "legal subscription", "ongoing legal support" ], "areaServed": [ "Germany", "European Union", "United Kingdom", "United States", "Singapore" ] } }, { "@type": "Offer", "itemOffered": { "@type": "Service", "name": "M&A Preparation", "description": "Get ready for acquisition interest", "serviceType": [ "M&A preparation", "acquisition", "due diligence", "exit" ], "areaServed": [ "Germany", "European Union", "United Kingdom", "United States", "Singapore" ] } }, { "@type": "Offer", "itemOffered": { "@type": "Service", "name": "Restructuring & Insolvency", "description": "From the first liquidity check to the restructuring itself", "serviceType": [ "restructuring", "insolvency", "StaRUG", "self-administration", "insolvency plan", "director liability" ], "areaServed": [ "Germany", "European Union", "United Kingdom", "United States", "Singapore" ] } } ] }, "contactPoint": { "@type": "ContactPoint", "contactType": "sales", "email": "contact@compound.law", "availableLanguage": [ "English", "German" ], "areaServed": [ "DE", "AT", "CH", "EU", "GB", "US", "SG" ] }, "email": "contact@compound.law", "sameAs": [ "https://www.linkedin.com/company/compoundlawfirm", "https://x.com/CompoundLawFirm" ], "knowsAbout": [ "Commercial Contracts", "enterprise contracts", "MSA", "DPA", "sales contracts", "International Employment", "international employment", "hiring abroad", "employment contracts", "VSOP/ESOP Setup", "VSOP", "ESOP", "employee stock options", "equity incentives", "Funding Round Support", "funding round", "term sheet", "SHA", "due diligence", "cap table", "Corporate Housekeeping", "corporate governance", "board resolutions", "shareholder register", "Data Protection & Privacy", "GDPR", "data protection", "privacy", "cookies", "data breach response", "GDPR fines", "Art. 82 GDPR", "AI Act Compliance", "AI Act", "AI compliance", "AI governance", "EU AI regulation", "IP & Competition", "IP protection", "intellectual property", "trademarks", "trademark enforcement", "warning letters", "preliminary injunctions", "unfair competition", "software licensing", "open source compliance", "Fractional General Counsel", "fractional GC", "fractional general counsel", "outsourced legal", "legal retainer", "FinTech Compliance", "fintech compliance", "BaFin", "banking regulation", "AML", "KYC", "Legal Retainer", "legal subscription", "ongoing legal support", "M&A Preparation", "M&A preparation", "acquisition", "exit", "Restructuring & Insolvency", "restructuring", "insolvency", "StaRUG", "self-administration", "insolvency plan", "director liability" ] }, { "@context": "https://schema.org", "@type": "Article", "headline": "AI Act and Pharmaceuticals: Compliance for German Pharma (2026)", "description": "How the EU AI Act affects drug discovery, clinical trials, and pharmaceutical AI in Germany.", "image": "https://compound.law/assets/images/ai-act/ai_act_2.webp", "datePublished": "2026-01-29T00:00:00.000Z", "dateModified": "2026-01-29T00:00:00.000Z", "author": { "@type": "Person", "name": "Dr. Markus Dreißigacker", "image": "https://compound.law/assets/images/team/markusdreissigacker.webp" }, "publisher": { "@type": "Organization", "@id": "https://compound.law/#organization", "name": "Compound Law" }, "mainEntityOfPage": { "@type": "WebPage", "@id": "https://compound.law/en-DE/ai-act/pharmaceuticals/" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://compound.law/en-DE/" }, { "@type": "ListItem", "position": 2, "name": "AI Act by Industry", "item": "https://compound.law/en-DE/ai-act/" }, { "@type": "ListItem", "position": 3, "name": "AI Act and Pharmaceuticals: Compliance for German Pharma", "item": "https://compound.law/en-DE/ai-act/pharmaceuticals/" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Is drug discovery AI regulated?", "acceptedAnswer": { "@type": "Answer", "text": "Research AI has flexibility. Heavy regulation begins when AI affects patients or enters clinical application." } }, { "@type": "Question", "name": "What about AI in clinical trials?", "acceptedAnswer": { "@type": "Answer", "text": "Patient-affecting AI needs full compliance. Trial optimization tools are generally lower risk." } }, { "@type": "Question", "name": "Does GMP cover AI requirements?", "acceptedAnswer": { "@type": "Answer", "text": "Partly. GMP provides foundation, but AI Act adds AI-specific requirements for manufacturing AI." } }, { "@type": "Question", "name": "Does the EU AI Act apply to GxP-regulated AI systems in Germany?", "acceptedAnswer": { "@type": "Answer", "text": "Yes. AI systems deployed in GxP-regulated environments — GMP, GCP, and GVP — are subject to EU AI Act requirements in Germany and across the EU. The risk classification under Annex III of the EU AI Act applies to AI performing safety-relevant functions in manufacturing, clinical trials, and pharmacovigilance. The obligations overlap substantially with existing GxP requirements, particularly around documentation, validation, and change control. Pharmaceutical companies must assess each AI system individually and implement the technical documentation requirements under Articles 11–17. Compound Law advises pharma companies in Germany and the DACH region on aligning EU AI Act obligations with GAMP 5 and ICH requirements." } }, { "@type": "Question", "name": "What is the EU AI Act deadline for pharmaceutical companies in 2026?", "acceptedAnswer": { "@type": "Answer", "text": "The EU AI Act's high-risk AI provisions become mandatory on 2 August 2026. For pharmaceutical companies, this means AI systems in GxP-regulated processes — particularly those performing safety-relevant functions in manufacturing, clinical trials, or pharmacovigilance — must meet full documentation, conformity assessment, and quality management obligations by that date. Companies that have not yet classified their AI systems or begun compliance work should act immediately; the compliance window is now short. The deadline also applies to AI diagnostic tools qualifying as medical devices, where MDR conformity assessment is recognised under Article 28 EU AI Act but does not replace the substantive AI Act requirements." } }, { "@type": "Question", "name": "Who can help pharmaceutical companies implement the EU AI Act for regulated processes?", "acceptedAnswer": { "@type": "Answer", "text": "Compound Law advises pharmaceutical companies in Germany and the DACH region on EU AI Act compliance for regulated processes — from risk classification to GAMP 5-compatible documentation and notified body coordination. Our team covers the full compliance scope: GxP interface analysis, technical documentation under Articles 11–17, quality management system integration, and post-market monitoring obligations. We work with pharmaceutical companies of all sizes, from large DACH manufacturers to clinical-stage biotechs entering regulated processes. See our [AI medical diagnosis compliance guide](/en-DE/compliance/ai-medical-diagnosis/) and [healthcare AI Act page](/en-DE/ai-act/healthcare/) for related MDR and MedTech compliance considerations." } } ] } ] ```